Therefore, the combination therapy of, (1) activating the SLCO4C1 expression by statins, (2) reducing the plasma IS concentration by the administration of AST-120 and (3) administering GATA inhibitor to suppress GATA factors induced by IS, could be a more effective remedy for the excretion of uremic toxins and preservation of renal function in CKD patients (Figure 7). This evidence concerns the gene QRSL1 and chronic kidney disease.